Sign in

Trial result ·

Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study.

Written based on 1 research study on PubMed, searched on 8 Nov 2026.

What was studied

This early trial tested olaparib plus tremelimumab. The women had recurrent ovarian cancer. All had a BRCA1 or BRCA2 gene change. In all, 50 women took part. It was a single-arm trial at several sites. Safety and response were the aims. The first part had 3 people.

What they found

No new side effects were found in the first 3 people. In the safety group of 49, severe non-blood side effects were common. Many people stopped tremelimumab. The trial did not meet its main goal. Median time without growth was 3.0 months. Median overall survival was 24.3 months. In 6 people, time without growth passed 12 months. Low VSTM5 or IFIT1B levels were linked to benefit.

What it means for patients

The authors say the trial did not meet its efficacy goal. They say 6 people did well for over 12 months. They say biomarkers are needed to select treatments for these women.

Why it is not certain yet

It was a single-arm trial with no comparison group. The women had many earlier treatments. The biomarker findings were exploratory and made after the fact. Links to biomarkers are not proof of benefit. Only 6 people had long benefit.

Source

Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study.

PubMed · PMID 42982866

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Ovarian cancer publications
Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study. · Ovarian cancer news explained – Frontlight Research